Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 11/2011

01.11.2011 | Article

Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades

verfasst von: E. Ahlstrand, K. Svensson, L. Persson, U. Tidefelt, B. Söderquist

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to determine if there was a long-term increase in glycopeptide minimum inhibitory concentration (MIC) values, MIC creep, among bloodstream isolates of Staphylococcus epidermidis and S. haemolyticus isolated from patients with hematological malignancies. We conducted a retrospective single-center study where all positive blood cultures of S. epidermidis (n = 387) and S. haemolyticus (n = 19) isolated from patients with hematological malignancies during three decades, 1980 to 2009, were re-evaluated for the presence of reduced susceptibility to vancomycin and teicoplanin. Three different methods for the detection of reduced susceptibility to glycopeptides were used; standard Etest, macromethod Etest, and glycopeptide resistance detection (GRD) Etest. The median MIC value for vancomycin was 2 mg/L. MIC values for vancomycin and teicoplanin did not show any statistically significant increase during the study period. The presence of heterogeneously glycopeptide-intermediate staphylococci (hGIS) was analyzed among 405 coagulase-negative staphylococci (CoNS) isolates. hGIS were found in 31–45% of the CoNS isolates by the macromethod Etest and in 53–67% by the GRD Etest during the three decades. In conclusion, we did not observe any long-term glycopeptide MIC creep determined by the standard Etest, although a high and increasing proportion of heterogeneous vancomycin resistance was observed.
Literatur
1.
Zurück zum Zitat Rogers KL, Fey PD, Rupp ME (2009) Coagulase-negative staphylococcal infections. Infect Dis Clin North Am 23(1):73–98PubMedCrossRef Rogers KL, Fey PD, Rupp ME (2009) Coagulase-negative staphylococcal infections. Infect Dis Clin North Am 23(1):73–98PubMedCrossRef
2.
Zurück zum Zitat Wilson AP, O’Hare MD, Felmingham D, Grüneberg RN (1986) Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 2(8513):973PubMedCrossRef Wilson AP, O’Hare MD, Felmingham D, Grüneberg RN (1986) Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 2(8513):973PubMedCrossRef
3.
Zurück zum Zitat Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316(15):927–931PubMedCrossRef Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316(15):927–931PubMedCrossRef
4.
Zurück zum Zitat Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A; The Linezolid Study Group (2000) Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 46(6):931–940PubMedCrossRef Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A; The Linezolid Study Group (2000) Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 46(6):931–940PubMedCrossRef
5.
Zurück zum Zitat Santos Sanches I, Mato R, de Lencastre H, Tomasz A (2000) Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 6(3):199–211PubMedCrossRef Santos Sanches I, Mato R, de Lencastre H, Tomasz A (2000) Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 6(3):199–211PubMedCrossRef
6.
Zurück zum Zitat de Neeling AJ, van Leeuwen WJ, Schouls LM, Schot CS, van Veen-Rutgers A, Beunders AJ, Buiting AG, Hol C, Ligtvoet EE, Petit PL, Sabbe LJ, van Griethuysen AJ, van Embden JD (1998) Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989–1995. J Antimicrob Chemother 41(1):93–101PubMedCrossRef de Neeling AJ, van Leeuwen WJ, Schouls LM, Schot CS, van Veen-Rutgers A, Beunders AJ, Buiting AG, Hol C, Ligtvoet EE, Petit PL, Sabbe LJ, van Griethuysen AJ, van Embden JD (1998) Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989–1995. J Antimicrob Chemother 41(1):93–101PubMedCrossRef
7.
Zurück zum Zitat Felmingham D, Brown DF, Soussy CJ; European Glycopeptide Resistance Survey Study Group (1998) European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. Diagn Microbiol Infect Dis 31(4):563–571PubMedCrossRef Felmingham D, Brown DF, Soussy CJ; European Glycopeptide Resistance Survey Study Group (1998) European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. Diagn Microbiol Infect Dis 31(4):563–571PubMedCrossRef
8.
Zurück zum Zitat Froggatt JW, Johnston JL, Galetto DW, Archer GL (1989) Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 33(4):460–466PubMed Froggatt JW, Johnston JL, Galetto DW, Archer GL (1989) Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 33(4):460–466PubMed
9.
Zurück zum Zitat Goldstein FW, Coutrot A, Sieffer A, Acar JF (1990) Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 34(5):899–900PubMed Goldstein FW, Coutrot A, Sieffer A, Acar JF (1990) Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 34(5):899–900PubMed
10.
Zurück zum Zitat Grüneberg RN, Hryniewicz W (1998) Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Int J Antimicrob Agents 10(4):271–277PubMedCrossRef Grüneberg RN, Hryniewicz W (1998) Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Int J Antimicrob Agents 10(4):271–277PubMedCrossRef
11.
Zurück zum Zitat Herwaldt L, Boyken L, Pfaller M (1991) In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 10(12):1007–1012PubMedCrossRef Herwaldt L, Boyken L, Pfaller M (1991) In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 10(12):1007–1012PubMedCrossRef
12.
Zurück zum Zitat Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW (2000) Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 44(12):3374–3380PubMedCrossRef Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW (2000) Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 44(12):3374–3380PubMedCrossRef
13.
Zurück zum Zitat Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350(9092):1670–1673PubMedCrossRef Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350(9092):1670–1673PubMedCrossRef
14.
Zurück zum Zitat Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340(7):517–523PubMedCrossRef Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340(7):517–523PubMedCrossRef
15.
Zurück zum Zitat Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE (2000) Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother 44(11):3122–3126PubMedCrossRef Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE (2000) Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother 44(11):3122–3126PubMedCrossRef
16.
Zurück zum Zitat Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A (1998) Recurrent peritonitis in a patient on dialysis and prophylactic vancomycin. Lancet 351(9106):880–881PubMedCrossRef Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A (1998) Recurrent peritonitis in a patient on dialysis and prophylactic vancomycin. Lancet 351(9106):880–881PubMedCrossRef
17.
Zurück zum Zitat Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A (1999) Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 37(1):39–44PubMed Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A (1999) Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 37(1):39–44PubMed
18.
Zurück zum Zitat Van Der Zwet WC, Debets-Ossenkopp YJ, Reinders E, Kapi M, Savelkoul PH, Van Elburg RM, Hiramatsu K, Vandenbroucke-Grauls CM (2002) Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit. J Clin Microbiol 40(7):2520–2525CrossRef Van Der Zwet WC, Debets-Ossenkopp YJ, Reinders E, Kapi M, Savelkoul PH, Van Elburg RM, Hiramatsu K, Vandenbroucke-Grauls CM (2002) Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit. J Clin Microbiol 40(7):2520–2525CrossRef
19.
Zurück zum Zitat Gould IM (2008) Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31(Suppl 2):1–9PubMedCrossRef Gould IM (2008) Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31(Suppl 2):1–9PubMedCrossRef
20.
Zurück zum Zitat Bertin M, Muller A, Bertrand X, Cornette C, Thouverez M, Talon D (2004) Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 23(5):375–379PubMedCrossRef Bertin M, Muller A, Bertrand X, Cornette C, Thouverez M, Talon D (2004) Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 23(5):375–379PubMedCrossRef
21.
Zurück zum Zitat Boisson K, Thouverez M, Talon D, Bertrand X (2002) Characterisation of coagulase-negative staphylococci isolated from blood infections: incidence, susceptibility to glycopeptides, and molecular epidemiology. Eur J Clin Microbiol Infect Dis 21(9):660–665PubMedCrossRef Boisson K, Thouverez M, Talon D, Bertrand X (2002) Characterisation of coagulase-negative staphylococci isolated from blood infections: incidence, susceptibility to glycopeptides, and molecular epidemiology. Eur J Clin Microbiol Infect Dis 21(9):660–665PubMedCrossRef
22.
Zurück zum Zitat Tacconelli E, Tumbarello M, Donati KG, Bettio M, Spanu T, Leone F, Sechi LA, Zanetti S, Fadda G, Cauda R (2001) Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case–control study. Clin Infect Dis 33(10):1628–1635PubMedCrossRef Tacconelli E, Tumbarello M, Donati KG, Bettio M, Spanu T, Leone F, Sechi LA, Zanetti S, Fadda G, Cauda R (2001) Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case–control study. Clin Infect Dis 33(10):1628–1635PubMedCrossRef
23.
Zurück zum Zitat Biavasco F, Vignaroli C, Varaldo PE (2000) Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 19(6):403–417PubMedCrossRef Biavasco F, Vignaroli C, Varaldo PE (2000) Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 19(6):403–417PubMedCrossRef
24.
Zurück zum Zitat Hiramatsu K, Hanaki H (1998) Glycopeptide resistance in staphylococci. Curr Opin Infect Dis 11(6):653–658PubMedCrossRef Hiramatsu K, Hanaki H (1998) Glycopeptide resistance in staphylococci. Curr Opin Infect Dis 11(6):653–658PubMedCrossRef
25.
Zurück zum Zitat Cherif H, Kronvall G, Björkholm M, Kalin M (2003) Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4(6):420–426PubMedCrossRef Cherif H, Kronvall G, Björkholm M, Kalin M (2003) Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4(6):420–426PubMedCrossRef
26.
Zurück zum Zitat Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39(7):2439–2444PubMedCrossRef Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39(7):2439–2444PubMedCrossRef
27.
Zurück zum Zitat Leonard SN, Rossi KL, Newton KL, Rybak MJ (2009) Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 63(3):489–492PubMedCrossRef Leonard SN, Rossi KL, Newton KL, Rybak MJ (2009) Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 63(3):489–492PubMedCrossRef
28.
Zurück zum Zitat Maniati M, Petinaki E, Kontos, Maniatis AN, Spiliopoulou I, Petropoulou-Mylona D, Malamou-Lada H, Spaliara L, Koutsia-Carouzou C (2005) Rapid increase in numbers of Staphylococcus epidermidis strains with reduced susceptibility to teicoplanin in Greece. Int J Antimicrob Agents 25(4):346–348PubMedCrossRef Maniati M, Petinaki E, Kontos, Maniatis AN, Spiliopoulou I, Petropoulou-Mylona D, Malamou-Lada H, Spaliara L, Koutsia-Carouzou C (2005) Rapid increase in numbers of Staphylococcus epidermidis strains with reduced susceptibility to teicoplanin in Greece. Int J Antimicrob Agents 25(4):346–348PubMedCrossRef
29.
Zurück zum Zitat Trueba F, Garrabe E, Hadef R, Fabre R, Cavallo JD, Tsvetkova K, Chesneau O (2006) High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol 44(5):1922–1923PubMedCrossRef Trueba F, Garrabe E, Hadef R, Fabre R, Cavallo JD, Tsvetkova K, Chesneau O (2006) High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol 44(5):1922–1923PubMedCrossRef
30.
Zurück zum Zitat Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46(2):193–200PubMedCrossRef Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46(2):193–200PubMedCrossRef
31.
Zurück zum Zitat Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52(9):3315–3320PubMedCrossRef Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52(9):3315–3320PubMedCrossRef
32.
Zurück zum Zitat Srinivasan A, Dick JD, Perl TM (2002) Vancomycin resistance in staphylococci. Clin Microbiol Rev 15(3):430–438PubMedCrossRef Srinivasan A, Dick JD, Perl TM (2002) Vancomycin resistance in staphylococci. Clin Microbiol Rev 15(3):430–438PubMedCrossRef
33.
Zurück zum Zitat Cremniter J, Slassi A, Quincampoix JC, Sivadon-Tardy V, Bauer T, Porcher R, Lortat-Jacob A, Piriou P, Judet T, Herrmann JL, Gaillard JL, Rottman M (2010) Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol 48(4):1428–1431PubMedCrossRef Cremniter J, Slassi A, Quincampoix JC, Sivadon-Tardy V, Bauer T, Porcher R, Lortat-Jacob A, Piriou P, Judet T, Herrmann JL, Gaillard JL, Rottman M (2010) Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol 48(4):1428–1431PubMedCrossRef
34.
Zurück zum Zitat Natoli S, Fontana C, Favaro M, Bergamini A, Testore GP, Minelli S, Bossa MC, Casapulla M, Broglio G, Beltrame A, Cudillo L, Cerretti R, Leonardis F (2009) Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. BMC Infect Dis 9:83PubMedCrossRef Natoli S, Fontana C, Favaro M, Bergamini A, Testore GP, Minelli S, Bossa MC, Casapulla M, Broglio G, Beltrame A, Cudillo L, Cerretti R, Leonardis F (2009) Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. BMC Infect Dis 9:83PubMedCrossRef
35.
Zurück zum Zitat Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29(11):1275–1279PubMedCrossRef Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29(11):1275–1279PubMedCrossRef
36.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef
Metadaten
Titel
Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades
verfasst von
E. Ahlstrand
K. Svensson
L. Persson
U. Tidefelt
B. Söderquist
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2011
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1228-8

Weitere Artikel der Ausgabe 11/2011

European Journal of Clinical Microbiology & Infectious Diseases 11/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.